Status:
COMPLETED
BMS-741672 for Diabetic Neuropathic Pain
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Neuropathic Pain
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of the study is to determine whether BMS-741672 improves neuropathic pain in diabetic patients.
Eligibility Criteria
Inclusion
- Type 1 or 2 diabetics with painful, distal, symmetrical, sensory-motor neuropathy attributed to diabetes, of at least 12 months duration
- Screening HbA1c of ≥ 7% and ≤ 10%
- BMI ≤ 40 kg/m2
Exclusion
- Patients with clinically significant, progressive, or potentially unstable disease of any body system including cardiovascular, gastrointestinal, central nervous system (CNS), psychiatric, endocrine (other than diabetes), tuberculosis or renal
- Women of childbearing potential
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00683423
Start Date
July 1 2008
End Date
February 1 2009
Last Update
October 12 2015
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
University Clinical Investigators, Inc.
Tustin, California, United States, 92780
2
Palm Beach Neurological Center
Palm Beach Gardens, Florida, United States, 33418
3
Comprehensive Neurosciences, Inc.
St. Petersburg, Florida, United States, 33702
4
The Pain & Rehabilitation Clinic Of Chicago
Chicago, Illinois, United States, 60610